Recently published…

• Clarke N.A., Edwards D, Clarke F. How To Manage Dementia in General Practice. British Medical Journal Books; Wiley-Blackwell. Chichester: Publisher: John Wiley and Sons Ltd. (2013): 166 pages.
• Clarke N.A., Hartman T, Jones E.L.,Ballard C.G., Francis P.T., (2011) Antipsychotic medication is associated with selective alterations in ventricular cerebrospinal fluid Aß 40 and tau in patients with intractable unipolar depression. International Journal of Geriatric Psychiatry (26) 1283-1291.
• Clarke N.A., Hartmann T, Tomic I, Jones E.L., Ballard C.G., Francis P.T., (2008) Neuroleptic medication is associated with selective alterations in VCSF AB40 and tau in patients with intractable unipolar depression. Alzheimer’s Association International Conference for Alzheimer’s Disease, Chicago, Ill. (Poster/Abstract).

Publications to date…

1. M.Hughes, N.Clarke, L.Forbes, D.G.Colin-Jones (1986). Lesson of the week. A Case of Scurvy. Queen Alexandra Hospital, Portsmouth. British Medical Journal 293, 366.
2. P.T.Francis, M-T. Webster, A.W.Procter, N.A.Clarke, D.M.Bowen, R.Doshi, D.M.A.Mann, D.Neary (1993). Soluble ß-amyloid precursor protein and pyramidal neuron loss. Lancet 341,431.
3. N.A.Clarke, A.W.Procter, M-T.Webster, P.T.Francis, A.D.Hodgkiss, D.M.Bowen (1993). Effect of Lithium therapy and site of origin on cerebrospinal fluid ß-amyloid precursor protein derivatives. Biochemical Society Transactions 21, 242S.
4. N.A.Clarke (1993). Piercing the clouds of severe gloom. First, second and third line options in the treatment of chronic depression. Doctor 15.4.1993, 52-53.
5. N.A.Clarke (1993). What the eye doesn’t see; drugs psychiatrists and GPs don’t know their patients are on. Bulletin of the Royal College of Psychiatrists, 17,469-470.
6. N.A.Clarke, A.W.Procter, M-T.Webster, P.T.Francis, D.M.Bowen (1993). ß-amyloid precursor protein (APP) in lumbar and ventricular fluid of live patients. The Biochemical Society 646th Meeting. Poster/ Abstract.
7. P.T.Francis, N.A.Clarke, A.W.Procter, M-T.Webster, D.M.Bowen (1993). Drug therapy and ß-amyloid precursor protein (APP) of cortical pyramidal neurones. The Society for Neuroscience Annual Meeting, Washington D.C. Poster/ Abstract.
8. N.A.Clarke, M-T.Webster, P.T.Francis, A.W.Procter, D.M.Bowen (1993). Drug therapy and ß-Amyloid precursor protein (APP) of cortical pyramidal neurones. British Association for Psychopharmacology Summer Meeting. Oral presentation/Abstract.
9. N.A.Clarke, A.W.Procter, A.D.Hodgkiss, P.K.Bridges(1993). Drug therapy and ß-amyloid precursor protein (APP) of cortical pyramidal neurones. Guy’s and St Thomas’s Hospitals 3rd Annual Research Day, St Thomas’s Hospital. Poster/Abstract.
10. N.A.Clarke, M-T.Webster, P.T.Francis, A.W.Procter, A.D.Hodgkiss, D.M. Bowen (1993). ß-Amyloid Precursor Protein-like immunoreactivity can be altered in humans by drugs affecting neurotransmitter function. Neurodegeneration 2, 243-24.
11. P.T.Francis, I.P.Chessell, M-T.Webster, N.A.Clarke, A.W.Procter, J.T.Alder, C.P.L-H.Chen, M.Qume, S.Zeman, S.Dijk, D.M.Bowen. Is Improvement of Cholinergic Transmission the Correct Strategy for Alzheimer’s Disease? In: K.Iqbal, J.A.Mortimer, B.Winblad, H.M.Wisniewski (eds) Recent Advances in Alzheimer’s Disease and Related Disorders. Chichester: Publisher: John Wiley & Sons Ltd, 1995: 273-282.
12. A.W.Procter, P.T.Francis, C.P.L-H.Chen, I.A.Chessell, S Dijk, N.A.Clarke, M-T Webster, D.M.Bowen.The neurochemical pathology of Alzheimer’s disease. In: D.Dawbarn & S.J.Allen (eds) Neurobiology of Alzheimer’s Disease. Oxford:Bios Scientific Publishers Ltd, 1995: Chapter7.
13. N.A.Clarke, P.T.Francis, L.M.Brown, M-T.Webster, A.W.Procter, D.M.Bowen (1995). Psychotropics and concentrations of APLP2 in ventricular CSF of depressed patients. British Association for Psychopharmacology Summer Meeting.Poster/Abstract.
14. P.T.Francis, N.A.Clarke, L.M.Brown, M-T.Webster, A.W.Procter, D.M.Bowen (1995). Psychotropic drug treatment and concentrations of Amyloid Precursor-like Protein in ventricular CSF of depressed patients. The Society for Neuroscience 25th Annual Meeting, San Diego, California. Poster/Abstract.
15. P.T.Francis, S.N.Dijk, G.C.Stratmann, J.Tracy Alder, J.P.Chessell, M.T.Webster, C.P.L.-H. Chen, N.A. Clarke, A.W. Procter, D.M. Bowen (1996). Rationale of Cholinomimetic Therapy for Alzheimer’s Disease. In: Abraham Fisher (ed) Neuroscience Intelligence Unit – Muscarinic Agonists and the Treatment of Alzheimer’s Disease. (R.G. Landes Company, Austin). 21-38.
16. N.A.Clarke, A.J.Williams, M.D.Kopelman (2000). Case Study. Rapid eye movement sleep behaviour disorder, depression and cognitive impairment. British Journal of Psychiatry 176, 189-192.
17. Clarke N.A., Soininen H, Gustafson L, Minthon L, Alhainen K, Francis P.T. (2001) Tacrine may alter APP-like protein levels in the lumbar CSF of Alzheimer patients. Int J Ger Psychiatry (16) 1104-1106.
18. Clarke N.A., Tomic I, Hartmann T, Francis P.T. (2001) Soluble A1-40/1-42 in ventricular CSF from non-demented patients undergoing neurotransmitter-based pharmacotherapy. The Society for Neuroscience 31st Annual Meeting, San Diego, California (Poster/Abstract).
19. Clarke N.A., (2004) Treatments for dementias with different aetiologies are limited. Health and Ageing (June) 19-23.
20. Clarke N.A., Francis P.T. The neurochemistry of Alzheimer’s disease. In: Burns A, Ames D, O’Brien J (eds) Dementia. London: Edward Arnold (Publishers) Ltd, (2004): Chapter 29.
21. Clarke N.A., (2004) AD 2000:Design and conclusions. Lancet (364) 1215-1216.
22. Clarke N.A. & Francis P.T., (2005) Cholinergic and glutamatergic drugs in Alzheimer’s disease therapy. Expert Review of Neurotherapeutics 5(5), 671-682.
23. Clarke N.A., Hartmann T, Tomic I, Jones E.L., Ballard C.G., Francis P.T., (2008) Neuroleptic medication is associated with selective alterations in VCSF AB40 and tau in patients with intractable unipolar depression. Alzheimer’s Association International Conference for Alzheimer’s Disease, Chicago, Ill. (Poster/Abstract).
24. Clarke N.A., Hartman T, Jones E.L.,Ballard C.G., Francis P.T., (2011) Antipsychotic medication is associated with selective alterations in ventricular cerebrospinal fluid Aß 40 and tau in patients with intractable unipolar depression. International Journal of Geriatric Psychiatry (26) 1283-1291.
25. Clarke N.A., Edwards D, Clarke F. How To Manage Dementia in General Practice. British Medical Journal Books; Wiley-Blackwell. Chichester: Publisher: John Wiley and Sons Ltd. (2013): 166 pages.